RL648_81 (RL-81)

Drug Name: RL648_81 (RL-81)
Company: Tzounopoulos Lab
Location: US-Pennsylvania
Website: http://phrc.pitt.edu/people/thanos-tzounopoulos
Drug Type: Small Molecule
Conditions: Tinnitus
Mechanism Type: Neuronal hyperexcitability – Retigabine derivative
Mechanism: RL648_81 is a KCNQ2/3-specific channel activator that aims to reduce neuronal hyperexcitability by enabling neurons to return to the resting state upon firing. The drug, also known as RL-81 is a derivative of the FDA-approved epilepsy drug retigabine.
U.S. Status for ALS: N/A

References:
[1] Synthesis and Evaluation of Potent KCNQ2/3-specific Channel Activators. Kumar, M. et al. Mol Pharmacol. 2016 Jun;89(6):667-77.

Last updated February 13th, 2018

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail